目的 探討參桂膠囊聯(lián)合富馬酸比索洛爾片治療慢性心力衰竭的臨床療效。方法 選取2020年4月-2022年3月在項城市第一人民醫(yī)院就診的77例慢性心力衰竭患者,根據(jù)隨機數(shù)字表法分為對照組(38例)和治療組(39例)。對照組患者口服富馬酸比索洛爾片,1片/次,1次/d。治療組在對照組治療的基礎上口服參桂膠囊,4粒/次,3次/d。兩組患者共治療1個月。觀察兩組的臨床療效,比較兩組患者的心功能指標、心衰計分系統(tǒng)(LEE)評分和血清因子水平。結果 治療后,治療組的總有效率(94.87%)明顯高于對照組(78.95%)(P<0.05)。治療后,兩組的左心室射血分數(shù)(LVEF)明顯升高,左室后壁厚度(LVPW)、左心房壓力(LAP)明顯降低(P<0.05);治療組的LVEF明顯高于對照組,LVPW、LAP明顯低于對照組(P<0.05)。治療后,兩組的LEE評分明顯降低(P<0.05),且治療組LEE評分明顯低于對照組(P<0.05)。治療后,兩組的B型鈉尿肽(BNP)、半乳糖凝集素3(Gal-3)、結締組織生長因子(CTGF)水平低于治療前,且治療組的BNP、Gal-3、CTGT水平低于對照組,差異有統(tǒng)計學意義(P<0.05)。結論 參桂膠囊聯(lián)合比索洛爾治療慢性心力衰竭的療效確切,能改善心功能、控制心衰病情,調節(jié)BNP、Gal-3、CTGT水平。

Objective To investigate the clinical efficacy of Shengui Capsules combined with Bisoprolol Fumarate Tablets in treatment of chronic heart failure. Methods Patients (77 cases) with chronic heart failure in First People’s Hospital of Xiangcheng from April 2020 to March 2022 were divided into control group (38 cases) and treatment group (39 cases) according to random number table method. Patients in the control group were po administered with Bisoprolol Fumarate Tablets, 1 tablet/time, once daily. Patients in the treatment group were po administered with Shengui Capsules on the basis of the control group, 4 grains/time, three times daily. Patients in two groups were treated for 1 month. After treatment, the clinical efficacies were evaluated, and the cardiac function indexes, LEE scores, and serum factors level in two groups were compared. Results After treatment, the total effective rate (94.87%) of the treatment group was significantly higher than 78.95% of the control group (P＜0.05). After treatment, LVEF in two groups was significantly increased, but LVPW and LAP in two groups were significantly decreased (P＜0.05). LVEF of the treatment group was significantly higher than that of the control group, but LVPW and LAP were significantly lower than those of the control group (P＜0.05). After treatment, LEE score of two groups was significantly lower (P＜0.05), and LEE score of the treatment group was significantly lower than that of the control group (P＜0.05). After treatment, the levels of BNP, Gal-3, and CTGT in two groups were lower than those before treatment, and the serum factors levels in the treatment group were lower than those in the control group (P＜0.05). Conclusion Shengui Capsules combined with Bisoprolol Fumarate Tablets has clinical curative effect in treatment of chronic heart failure, can improve cardiac function, control the condition of heart failure, and regulate the levels of BNP, Gal-3 and CTGT.

R972

河南省醫(yī)學科技攻關計劃項目(2018020808)